Transcriptional elongation machinery controls vulnerability of breast cancer cells to PRC2 inhibitors
W. Xu, N. T. Chan, P. Liu, J. Huang, Y. Wang, I. M. Ong, L. Li
This study shows that CTR9 loss in breast cancer cells increases H3K27me3 levels and switches PRC2 subtype, making cells more sensitive to PRC2 inhibitors.
bioRxiv · Jan 8, 2020 · PreprintCancer Biology